She received her Ph.D. from Princeton University, where she uncovered the metabolic consequences of the anti-metabolite drug trimethoprim. As a postdoctoral fellow at MIT, she was awarded the DoD CDMRP PRCRP Visionary Postdoctoral Fellowship to investigate the role of specific pyruvate kinase isoform expression in cancer. She has publications in top journals including Nature, Molecular Cell, and Annual Review of Cell and Developmental Biology. Her laboratory at Michigan State University focuses on understanding the role of metabolism in supporting cancer proliferation, heterogeneity, and metastasis. Her team combines powerful mass spectrometry, cell biology, and genetic models of cancer to investigate metabolic regulation in this complex disease. Dr. Lunt aims to rationally design more effective, personalized therapies for cancer based on metabolic targeting.